CareDx, Inc.CDNAEarnings & Financial Report
CareDx, Inc. is a leading precision medicine company dedicated to organ transplant patient care. It develops and commercializes diagnostic tests for rejection surveillance, digital health management tools, and supportive clinical services, catering to transplant clinicians, patients, and healthcare systems across North America and European core markets.
Revenue
$100.1M
Gross Profit
N/A
Operating Profit
$-246.0K
Net Profit
$1.7M
Gross Margin
N/A
Operating Margin
-0.2%
Net Margin
1.7%
YoY Growth
20.7%
EPS
$0.03
CareDx, Inc. Q3 FY2025 Financial Summary
CareDx, Inc. reported revenue of $100.1M (up 20.7% YoY) for Q3 FY2025, with a net profit of $1.7M (up 115.7% YoY) (1.7% margin).
Key Financial Metrics
| Total Revenue | $100.1M |
|---|---|
| Net Profit | $1.7M |
| Gross Margin | N/A |
| Operating Margin | -0.2% |
| Report Period | Q3 FY2025 |
Revenue Breakdown
CareDx, Inc. Q3 FY2025 revenue of $100.1M breaks down across 3 segments, led by Services at $72.2M (72.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Services | $72.2M | 72.1% |
| Patient And Digital Solutions | $15.4M | 15.4% |
| Products | $12.5M | 12.5% |
CareDx, Inc. Revenue by Segment — Quarterly Trend
CareDx, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Services and Patient And Digital Solutions) has evolved quarter over quarter.
| Segment | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 |
|---|---|---|---|---|
| Services | — | $78.4M | $72.2M | $62.0M |
| Patient And Digital Solutions | — | $16.8M | $15.4M | $12.8M |
| Products | — | $13.3M | $12.5M | $11.8M |
CareDx, Inc. Annual Revenue by Year
CareDx, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $379.8M).
| Year | Annual Revenue |
|---|---|
| 2025 | $379.8M |
| 2024 | $333.8M |
| 2023 | $280.3M |
| 2022 | $321.8M |
CareDx, Inc. Quarterly Revenue & Net Profit History
CareDx, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $117.7M | +39.0% | $2.8M | 2.4% |
| Q4 FY2025 | $108.4M | +25.2% | $-4.1M | -3.8% |
| Q3 FY2025 | $100.1M | +20.7% | $1.7M | 1.7% |
| Q2 FY2025 | $86.7M | -6.1% | $-8.6M | -9.9% |
| Q1 FY2025 | $84.7M | +17.5% | $-10.4M | -12.2% |
| Q4 FY2024 | $86.6M | +32.0% | $87.7M | 101.3% |
| Q3 FY2024 | $82.9M | +23.4% | $-10.6M | -12.8% |
| Q2 FY2024 | $92.3M | +31.3% | $-4.6M | -5.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $92.3M | $82.9M | $86.6M | $84.7M | $86.7M | $100.1M | $108.4M | $117.7M |
| YoY Growth | 31.3% | 23.4% | 32.0% | 17.5% | -6.1% | 20.7% | 25.2% | 39.0% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $466.8M | $477.0M | $491.1M | $489.6M | $444.3M | $432.3M | $413.2M | $411.1M |
| Liabilities | $202.1M | $203.7M | $112.6M | $110.3M | $116.9M | $121.2M | $110.1M | $97.5M |
| Equity | $264.7M | $273.2M | $378.4M | $379.3M | $327.4M | $311.1M | $303.1M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $18.9M | $12.5M | $21.9M | $-26.6M | $9.9M | $37.4M | $21.4M | $4.3M |